Recent Studies Indicate the Company’s Novel Adjuvant Technology Elicits Immunity Via Intranasal or Intramuscular Administration
ANN ARBOR, Mich., (June 1, 2016) – NanoBio Corporation today announced that the company will present key data at the GTCbio 14th Vaccines Research & Development Conference in San Diego on June 3, 2016, demonstrating the advantages of its nanoemulsion (NE) adjuvant for use in the development of intramuscular vaccines for pandemic influenza and other diseases.
The primary research being presented at the conference was conducted under a five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Pursuant to the contract, NanoBio is developing both an intranasal and an intramuscular NE adjuvant for use with pandemic influenza vaccines. The studies were conducted using a plant-based recombinant H5 pandemic influenza antigen.
“The combined effort of researchers at NanoBio and the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan have led to the very significant discovery of a new NE adjuvant formulation that appears optimal for intramuscular administration,” said David Peralta, Chief Executive Officer, NanoBio. “Given most vaccines today are injected, this NE formulation has the potential to enhance the effectiveness of many intramuscular vaccines currently available and in development stages.”
“Our recent studies in mice demonstrate that intramuscular NE vaccination elicits robust antibody responses as well as the type of balanced cellular immunity we strive to achieve to protect against certain diseases,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. “We’ve observed this profile of immune response in the pandemic influenza studies being presented at the conference, as well as other studies testing the NE with several additional antigens.”
Fattom continued, “We have also confirmed that the NE is compatible with other intramuscular vaccine adjuvants. In studies testing such combination-adjuvant vaccines, we observe significant synergy particularly with respect to cell-mediated immunity. This may play an important role in the development of intramuscular vaccines that elicit the desired immune response required for durable efficacy against selected infectious diseases, cancers and allergies.”
Peralta noted, “Our future development efforts at NanoBio will continue to incorporate intranasal administration of NE vaccines, given our NE adjuvant’s unique ability to elicit both a systemic and mucosal immune response following this route of application. However, with this new discovery, we will increasingly also explore use of intramuscular NE vaccination as we seek to advance several vaccine candidates to human clinical studies in the years ahead.”
Following are details of NanoBio’s upcoming oral presentation at the GTCbio 14th Vaccines Research & Development Conference
Title: Novel Nanoemulsion-based Intramuscular Vaccine Adjuvant for H5N1 Pandemic Influenza
Date/Time: June 3, 2016 / 9:40 a.m. PT
Location: Catamaran Resort, San Diego, California
Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company’s NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.
NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, prophylactic and therapeutic HSV2, chlamydia and HIV. In addition, the company has licensed its NE adjuvant to Merck for use with intranasal vaccines for RSV and seasonal influenza.